Liver Cancer Therapeutics Market Report 2026

The liver cancer therapeutics market size has grown rapidly in recent years. It will grow from $2.94 billion in 2025 to $3.44 billion in 2026 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to rising global incidence of liver cancer, limited effectiveness of conventional chemotherapy, increased awareness of early diagnosis, expansion of oncology treatment centers, regulatory approvals of targeted therapies.

The liver cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.34 billion in 2030 at a compound annual growth rate (CAGR) of 16.5%. The growth in the forecast period can be attributed to growth in immuno-oncology pipelines, increasing prevalence of chronic liver diseases, advancements in biomarker-driven therapies, rising healthcare expenditure on cancer care, expansion of personalized oncology treatment strategies. Major trends in the forecast period include increasing adoption of immunotherapy in liver cancer, rising use of targeted therapies for advanced disease, growing preference for combination treatment regimens, expansion of precision medicine approaches, increasing clinical trials for novel liver cancer drugs.

The increasing incidence of hepatitis B infections is expected to drive the growth of the liver cancer therapeutics market in the coming years. Hepatitis B is a viral disease caused by the hepatitis B virus (HBV) that primarily affects the liver and can result in both acute and chronic health complications, including liver cancer. The rise in hepatitis B infections is partly linked to increased injection drug use, which spreads the virus through the sharing of contaminated needles and syringes. Liver cancer therapeutics are critical for managing hepatitis B infections, as chronic infection can cause ongoing liver inflammation and cellular damage, substantially raising the risk of developing malignant liver conditions over time. For example, in July 2025, according to the World Health Organization, a Switzerland-based health organization, approximately 1.2 million new HBV infections occur globally each year. Consequently, the rising incidence of hepatitis B infections is expected to fuel the growth of the liver cancer therapeutics market.

Major companies in the liver cancer therapeutics market are focusing on developing innovative therapies, such as prescription immunotherapy medications, to provide durable and long-lasting effects. Prescription immunotherapy medications are drugs that enhance or modulate the body’s immune system to target specific diseases, including cancer or chronic infections, by regulating immune responses. For example, in April 2025, Bristol Myers Squibb, a US-based biopharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval of Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC) - the most common form of primary liver cancer - that is either unresectable or metastatic, as a first-line treatment. This approval was based on results from the global Phase 3 randomized, open-label CheckMate-9DW trial, in which patients with metastatic or unresectable HCC who had not received prior systemic therapy were randomized to receive Opdivo plus Yervoy in combination with the investigator’s choice of tyrosine kinase inhibitor monotherapy (lenvatinib or sorafenib). The combination therapy demonstrated statistically significant improvements in overall survival (OS) and overall response rate (ORR) compared to the comparator arm, making it the only trial supporting an FDA approval in this setting that shows superior outcomes.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. Following the acquisition, Coherus’ immuno-oncology pipeline now includes four differentiated clinical-stage assets: toripalimab (anti-PD-1), casdozokitug (IL-27-targeted), CHS-114 (CCR8-targeted), and CHS-006 (TIGIT-targeted). Development efforts are focused on delivering breakthrough survival benefits for cancer patients, aiming to surpass the efficacy of current chemotherapy plus checkpoint inhibitor regimens. Surface Oncology Inc. is a US-based company specializing in the development of therapeutics for liver cancer.

Major companies operating in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, Onyx Pharmaceuticals Inc.

North America was the largest region in the liver cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liver cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the liver cancer therapeutics market by increasing costs of imported active pharmaceutical ingredients, biologic drugs, and advanced diagnostic technologies. These impacts are most evident in immunotherapy and targeted therapy segments, particularly across North America, Europe, and Asia-Pacific regions where cross-border drug supply is significant. Higher tariffs have contributed to elevated treatment costs in hospital and specialty oncology settings. Positively, tariffs have encouraged domestic drug manufacturing and strengthened regional oncology supply chains.

The liver cancer therapeutics market research report is one of a series of new reports that provides liver cancer therapeutics market statistics, including liver cancer therapeutics industry global market size, regional shares, competitors with a liver cancer therapeutics market share, detailed liver cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer therapeutics industry. This liver cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver cancer therapeutics include a range of medical strategies aimed at managing abnormal cell growth in the liver, an organ essential for critical metabolic and detoxification functions. These treatments are designed to target, control, or eliminate harmful cellular activity while preserving healthy tissue as much as possible.

The primary types of liver cancer therapeutics include hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Hepatocellular carcinoma (HCC) is a primary liver cancer that originates in hepatocytes, the main liver cells. It is a leading cause of cancer-related deaths worldwide, especially in regions with high prevalence of chronic liver diseases such as hepatitis B, hepatitis C, alcohol-related liver disease, and cirrhosis. Treatment options include targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others, and these therapies are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used by patients across pediatric and adult populations.

The liver cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostics and screening, personalized treatment planning, minimally invasive procedures, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer therapeutics market also includes sales of drug delivery systems, diagnostic kits, biologics and supportive medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.